Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide

Am J Hematol. 2013 Aug;88(8):719. doi: 10.1002/ajh.23470. Epub 2013 May 30.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Amyloidosis* / drug therapy
  • Amyloidosis* / mortality
  • Amyloidosis* / pathology
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / adverse effects*
  • Female
  • Follow-Up Studies
  • Humans
  • Lenalidomide
  • Male
  • Middle Aged
  • Neoplasms, Second Primary* / chemically induced
  • Neoplasms, Second Primary* / mortality
  • Neoplasms, Second Primary* / pathology
  • Retrospective Studies
  • Risk Factors
  • Thalidomide / administration & dosage
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives*

Substances

  • Angiogenesis Inhibitors
  • Thalidomide
  • Lenalidomide